Lymphocytic alveolitis: A surprising index of poor prognosis in patients with primary Sjogren's syndrome (Journal article)
Dalavanga, Y. A./ Voulgari, P. V./ Georgiadis, A. N./ Leontaridi, C./ Katsenos, S./ Vassiliou, M./ Drosos, A. A./ Constantopoulos, S. H.
Full metadata record
|dc.contributor.author||Dalavanga, Y. A.||en|
|dc.contributor.author||Voulgari, P. V.||en|
|dc.contributor.author||Georgiadis, A. N.||en|
|dc.contributor.author||Drosos, A. A.||en|
|dc.contributor.author||Constantopoulos, S. H.||en|
|dc.subject||Bronchoalveolar Lavage Fluid/cytology||en|
|dc.subject||Lung Diseases, Interstitial/etiology/mortality/*pathology||en|
|dc.title||Lymphocytic alveolitis: A surprising index of poor prognosis in patients with primary Sjogren's syndrome||en|
|heal.recordProvider||Πανεπιστήμιο Ιωαννίνων. Σχολή Επιστημών Υγείας. Τμήμα Ιατρικής||el|
|heal.abstract||Twelve years ago we reported that lymphocytic alveolitis [or bronchoalveolar lavage (BAL) lymphocytosis] correlates with clinical pulmonary involvement in primary Sjogren's syndrome (pSS). Our thesis was based on subtle clinical and functional evidence of interstitial lung disease (ILD) in pSS patients with "high lymphocytic alveolitis" (>15% lymphocytes in BAL). This report is a follow-up study of these patients. Basic clinical and functional re-evaluation of the 22 patients with pSS, studied in 1991, emphasized the differences between those with alveolitis and those without alveolitis. There was no significant functional decline. There were, however, two statistically significant differences between the two groups: (1) only patients with BAL lymphocytosis had to be treated with steroids (5/12 vs. 0/10, P < 0.05) and (2) only patients with BAL lymphocytosis had died in the mean time (6/12 vs. 0/10, P < 0.01). The causes of death were various. On only two occasions were they related to respiratory infections while there were no deaths from respiratory failure secondary to ILD. BAL lymphocytosis appears to be a surprisingly serious index of dismal prognosis in patients with pSS. We offer no unifying pathophysiologic mechanism for it and, therefore, all we propose is that BAL is performed early, in as many patients with pSS as possible. These patients should then be followed up systematically, in order to evaluate if BAL lymphocytosis has any pathophysiologic importance in the development of clinically serious pSS, which is serious enough to lead to death.||en|
|Appears in Collections:||Άρθρα σε επιστημονικά περιοδικά ( Ανοικτά)|
Files in This Item:
|Dalavanga-2006-Lymphocytic alveolit.pdf||188.5 kB||Adobe PDF||View/Open Request a copy|
Please use this identifier to cite or link to this item:This item is a favorite for 0 people.
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.